Westwood Wealth Management cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 46.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,282 shares of the company’s stock after selling 3,700 shares during the quarter. Westwood Wealth Management’s holdings in Johnson & Johnson were worth $759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently bought and sold shares of JNJ. Family CFO Inc bought a new stake in shares of Johnson & Johnson in the 4th quarter worth $26,000. RE Dickinson Investment Advisors LLC lifted its position in Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after purchasing an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC lifted its position in Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after purchasing an additional 120 shares in the last quarter. Professional Financial Advisors LLC lifted its position in Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after purchasing an additional 68 shares in the last quarter. Finally, Joseph P. Lucia & Associates LLC purchased a new position in shares of Johnson & Johnson in the first quarter valued at about $38,000. 68.78% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.35% of the stock is owned by insiders.
Johnson & Johnson Stock Down 1.7 %
Shares of NYSE JNJ opened at $164.27 on Monday. The company has a 50 day simple moving average of $173.07 and a 200-day simple moving average of $174.40. The company has a market capitalization of $431.90 billion, a P/E ratio of 23.91, a P/E/G ratio of 3.15 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.48 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.75%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on JNJ shares. Daiwa Capital Markets began coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Morgan Stanley upped their target price on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Finally, SVB Leerink reduced their price target on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $189.89.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.